Fate Therapeutics Inc (FATE)
4.085
0.00 (0.00%)
USD |
NASDAQ |
May 02, 16:00
4.085
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Revenue (TTM): 63.53M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 63.53M |
September 30, 2023 | 106.21M |
June 30, 2023 | 119.25M |
March 31, 2023 | 136.87M |
December 31, 2022 | 96.30M |
September 30, 2022 | 69.01M |
June 30, 2022 | 68.26M |
March 31, 2022 | 63.12M |
December 31, 2021 | 55.85M |
September 30, 2021 | 54.68M |
June 30, 2021 | 48.01M |
March 31, 2021 | 40.06M |
December 31, 2020 | 31.43M |
September 30, 2020 | 18.34M |
June 30, 2020 | 13.21M |
March 31, 2020 | 10.56M |
December 31, 2019 | 10.68M |
September 30, 2019 | 9.539M |
June 30, 2019 | 8.136M |
March 31, 2019 | 6.346M |
December 31, 2018 | 4.74M |
September 30, 2018 | 4.106M |
Date | Value |
---|---|
June 30, 2018 | 4.106M |
March 31, 2018 | 4.105M |
December 31, 2017 | 4.106M |
September 30, 2017 | 4.106M |
June 30, 2017 | 4.106M |
March 31, 2017 | 4.107M |
December 31, 2016 | 4.402M |
September 30, 2016 | 4.451M |
June 30, 2016 | 4.451M |
March 31, 2016 | 3.753M |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | 1.614M |
June 30, 2013 | 1.933M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
8.136M
Minimum
Jun 2019
136.87M
Maximum
Mar 2023
53.84M
Average
54.68M
Median
Sep 2021
Revenue (TTM) Benchmarks
Amicus Therapeutics Inc | 399.36M |
Regeneron Pharmaceuticals Inc | 13.12B |
Sarepta Therapeutics Inc | 1.243B |
ADMA Biologics Inc | 258.22M |
Ocular Therapeutix Inc | 58.44M |